Charles Riv­er’s CD­MO busi­ness slows; Lil­ly boosts GLP-1 ca­pac­i­ty; Te­va’s Is­rael sites 'u­naf­fect­ed'

Last year
Manufacturing

No­vavax’s trou­bles con­tin­ue as Covid vac­cine mak­er plans an­oth­er $300M+ in cost-cut­ting

Last year
People
Pharma

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Last year
R&D
Cell/Gene Tx

Ful­ly syn­thet­ic genome nears com­ple­tion in a step to­ward un­rav­el­ing ge­net­ic mys­ter­ies

Last year
R&D
Discovery

Take­da scores FDA ap­proval for $400M col­orec­tal can­cer ther­a­py

Last year
Pharma
FDA+

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

Last year
R&D
Pharma

Mer­ck KGaA’s Baven­cio no longer 'alone' in blad­der can­cer mar­ket, but growth op­por­tu­ni­ty re­mains

Last year
Pharma

So­ci­etal CD­MO trims pro­ject­ed 2023 sales rev­enue de­spite third-quar­ter earn­ings bump

Last year
Manufacturing

As­traZeneca puts down $185M up­front for PhI oral GLP-1 as it shoots for next-gen win

Last year
Deals
R&D

Sanofi CEO re­it­er­ates R&D bet is best long-term ap­proach, ad­dress­es probe on mar­ket ma­nip­u­la­tion al­le­ga­tions

Last year
People
Pharma

No­vo Nordisk to dis­con­tin­ue long-act­ing in­sulin Lev­emir next year amid in­com­ing 65% price cut

Last year
Pharma

FDA watch­dog ad­mon­ish­es Evofem for mar­ket­ing brochure for its con­tra­cep­tive Phexxi

Last year
Pharma
FDA+

Te­va says it's ac­tive­ly search­ing for late-stage pro­grams in next phase of growth strat­e­gy

Last year
Pharma

Mod­er­na de­buts first Spike­vax brand cam­paign with light­heart­ed tone to ‘nor­mal­ize’ Covid vac­ci­na­tions

Last year
Pharma
Marketing

FDA ap­proves an un­brand­ed ver­sion of megablock­buster Hu­mi­ra, but Ab­b­Vie says it won't 'cur­rent­ly' launch

Last year
Pharma
FDA+

Gilead’s HIV sales hit $4.7B in Q3, first six-month PrEP ap­proval planned in 2025

Last year
Pharma

Sen­ate Fi­nance Com­mit­tee unan­i­mous­ly ad­vances PBM, Medicare Part D re­forms

Last year
Pharma
FDA+

FDA+ roundup: Fi­nal guid­ance on the fastest on­col­o­gy drug ap­provals; Re­mote in­spec­tions fail to take off

Last year
FDA+

Up­dat­ed: Eli Lil­ly's tirzepatide breaks in­to obe­si­ty mar­ket with FDA ap­proval

Last year
Pharma
FDA+

Bay­er to pull fol­lic­u­lar lym­phoma drug Aliqopa from US mar­ket in an­oth­er blow to PI3K in­hibitor space

Last year
Pharma

Lyell lays off 25% of staff and CMO leaves as com­pa­ny fore­shad­ows first clin­i­cal da­ta next year

Last year
People
R&D

BioN­Tech’s ‘ex­ten­sive’ can­cer pipeline comes in­to fo­cus, with em­pha­sis on AD­Cs

Last year
Deals
R&D

Pyx­is On­col­o­gy lays off 20 em­ploy­ees; Xen­cor’s roy­al­ty sale to a pen­sion plan; Jazz part­ners with MD An­der­son

Last year
News Briefing

Sh­eryl Sand­berg-backed AI da­ta plat­form launch­es to per­son­al­ize fer­til­i­ty care

Last year
Health Tech
First page Previous page 248249250251252253254 Next page Last page
A service from the Financial Times